This trial is active, not recruiting.

Condition prostatic neoplasms
Treatments atorvastatin, placebo
Phase phase 2
Sponsor Tampere University Hospital
Collaborator University of Tampere
Start date August 2012
End date May 2016
Trial size 160 participants
Trial identifier NCT01821404, 2011-005438-20


This single-center, randomized, double-blind trial assesses the impact of short-term atorvastatin administration on proliferation activity, apoptotic rate and histological inflammation in prostate tissue.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose prevention
(Placebo Comparator)
Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
Similar capsules as in the atorvastatin arm, but without the active ingredient
Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
Capsules including 80 mg of atorvastatin

Primary Outcomes

time frame: Four weeks after recruitment
Ki-67 expression
time frame: Four weeks after recruitment
Histological inflammation
time frame: After prostatectomy
serum PSA
time frame: At recruitment and before prostatectomy

Secondary Outcomes

serum cholesterol
time frame: At recruitment and again four weeks after
Atorvastatin level in prostate tissue
time frame: Four weeks after recruitment

Eligibility Criteria

Male participants from 40 years up to 80 years old.

Inclusion Criteria: - Prostate cancer proven histologically in prostate biopsy - Radical prostatectomy selected as the first-line treatment - Willingness to participate and sign informed consent Exclusion Criteria: - Previous oncological treatments for any malignancy - Previous usage of statins, finasteride or dutasteride within a year prior to prostate cancer diagnosis - Clinically significant liver- or kidney insufficiency (plasma alanine aminotransferase level is twice over the recommended upper limit or serum creatinine level is over 170 µmol/l) - Previous adverse effects from cholesterol-lowering treatment - Ongoing use of drugs having interactions with statins (St John's Wort, HIV protease inhibitors, ciclosporin, macrolide antibiotics, fusidic acid, phenytoin, carbamazepine, dronedarone or oral antifungal medication)

Additional Information

Official title The Impact of Atorvastatin on Prostate Cancer - a Randomized, Pre-surgical Clinical Trial
Principal investigator Teemu J Murtola, M.D., Ph.D.
Description In this trial 160 men who have been diagnosed with prostate cancer, and whose first-line treatment will be radical prostatectomy (surgical removal of the prostate), are randomized to receive either 80 mg atorvastatin or placebo daily for 2-5 weeks until the operation. Blood cholesterol and serum PSA are measured before starting the study drug use and before the operation. After the operation change in PSA and histological inflammation, apoptotic rate and Ki-67 staining intensity are compared between atorvastatin-treated and placebo-treated men. The correlation between changes in serum cholesterol or prostate specific antigen (PSA) and the tissue characteristics is evaluated. After recruiting 60 men we will perform an interim analysis on primary end-points without breaking the blinding to treatment allocation. If we observe a statistically significant difference in all primary end-points, the trial will be stopped early and the results published. Additionally, atorvastatin concentration in the blood and the prostate tissue is measured with mass spectrometry to determine penetrance of atorvastatin into the prostate. DNA- and RNA-samples are obtained from the prostate tissue and the blood. These will be used to study how gene expression of statin- and cholesterol-modifying enzymes affects the responses observed in prostate tissue. As a secondary end-point we will measure recovery of erectile function after the operation and compare between the two study arms. Erectile function is measured using IIEF-5 questionnaire once before the operation and again 3, 6, 9 and 12 months from the prostatectomy.
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Tampere University Hospital.